Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | TYK2 | P29597 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | ATR | Q13535 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231779 | 0.90 | NAMPT (0.74) | NAMPTKCNK3 | |
| SCHEMBL5232957 | 0.87 | RAB9A (0.68) | POLBNCOR2KCNK9 | |
| SCHEMBL5233340 | 0.87 | KCNK3 (0.55) | KDRPOLBJAK2TYK2NAMPT | |
| SCHEMBL27874235 | 0.86 | KDR (0.63) | KDRPOLBHDAC3HDAC1HDAC2 | |
| SCHEMBL5230352 | 0.83 | MEN1 (0.62) | KDRPOLB | |
| SCHEMBL5231352 | 0.80 | KMT2A (0.56) | KDRNAMPTHDAC3HDAC1HDAC2 | |
| SCHEMBL7974510 | 0.80 | ATR (0.59) | KDRPOLBHTTATRADORA3 | |
| SCHEMBL939975 | 0.79 | ATR (0.49) | KDRATR | |
| SCHEMBL24202631 | 0.78 | SIRT1 (0.83) | POLBHTTJAK2TYK2HDAC2 | |
| N-Phenylbenzamide SCHEMBL5402750 | 0.78 | SIRT1 (0.83) | POLBHTTJAK2TYK2HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | claimed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | claimed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | KDR 1205/4885POLB 4718/4885HTT 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.